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and for prediction of all-cause mortality in PH patients.
Methods: In patients referred for PH screening (n = 216), the VGx was calculated semiautomatically
from the electrocardiogram and was defined as abnormal when less than 24 mV·ms. The VGx of PH
patients was compared with the VGx of patients without PH. The association between a reduced
VGx and mortality was investigated in PH patients.
Results: Patients with PH (n = 117) had a significantly reduced VGx: 14 ± 27 vs 45 ± 23 mV·ms, P b
.001. Furthermore, a severely reduced VGx (b0 mV·ms) was associated with increased mortality in PH
patients: hazard ratio, 1.025 (95% confidence interval, 1.006-1.045; P = .012) per mV·ms VGx decrease.
Conclusion: Reduced VGx is associated with the presence of PH and, more importantly, within PH
patients, a severely reduced VGx predicts mortality.
© 2012 Elsevier Inc. Open access under the Elsevier OA license. Introduction
Pulmonary hypertension (PH) is an uncommon but
serious disease, characterized by a mean pulmonary artery
pressure (MPAP) of 25 mm Hg or more.1 Pulmonary
hypertension can be caused by a primary disease process in
the pulmonary arteries, referred to as pulmonary arterial
hypertension (PAH).2,3 Furthermore, PH can be secondary
to, for example, left-sided heart disease, pulmonary paren-
chyma abnormalities, thromboembolic occlusion of the
pulmonary arteries, or other diseases that lead to pulmonary
vascular abnormalities.2,3 Because PH is a progressive
disease, irrespective of the cause, timely detection and
treatment are necessary to improve symptoms and
prognosis.4-6 However, symptoms are generally mild untiluthor. Department of Cardiology, Leiden University
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Open access under the Elsevier OA license. advanced stages of the disease, and regular screening for PH
is frequently required, specifically in patients who are at risk
for developing PAH (eg, patients with inflammatory
connective tissue diseases, portal hypertension, or congenital
heart disease). 7 Currently, the gold standard for PH
screening is echocardiography, in which the systolic
pulmonary artery pressure (SPAP) is derived through
estimation of the peak systolic right ventricular (RV)
pressure.8 Recently, the vectorcardiogram (VCG), synthe-
sized from the standard 12-lead electrocardiogram (ECG),
demonstrated to be of use for detection of elevated RV
pressure as a consequence of PH. In a case-control study, the
ECG of patients with idiopathic PAH was compared with the
ECG of matched healthy subjects.9 In that study, the
ventricular gradient (VG) vector projected on the x-axis
(VGx) was strongly associated with pulmonary artery
pressure. It was shown that the VGx has a positive value
in healthy subjects and steadily reduces to zero or becomes
negative with increasing RV afterload. In addition, the VGx
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detecting elevated RV pressure than other ECG and VCG
parameters. This indicated that quantitative ECG screening
could be a valuable tool for the recognition of elevated
pulmonary pressure in suspected idiopathic PAH patients.
However, it remained to be investigated whether the
observations were also applicable in the regular patient
population of suspected PH patients, in which comorbidity is
common.10 In addition, the association between a reduced
VGx and patient survival was not investigated. Therefore,
we investigated whether quantitative ECG screening with the
VGx could also be applied in the more heterogeneous patient
population that is regularly referred for PAH screening.
Furthermore, the association of a reduced VGx and all-cause
mortality was assessed.Fig. 1. Orientation and size of the VG. A, The VG is the resultant vector of
the QRS and T integral vector, which have the same orientations as the
regular QRS and T axes. B, The VGx previously demonstrated to be reduced
in patients with idiopathic PAH (dashed vector) as compared with healthy
subjects (gray vector).9 Positive X direction, right to left; positive Y
direction, anterior to posterior.Materials and methods
Consecutive patients who were referred for diagnosis and
treatment of suspected PAH were included in the current
analysis. First, all patients underwent the standard noninva-
sive screening protocol for PAH according to the interna-
tional guidelines.11,12 As part of this protocol, a 10-second,
12-lead ECG was obtained, and echocardiography was
performed. Second, if the noninvasive screening protocol
indicated the presence of PAH or when the absence of
elevated pulmonary artery pressure could not be established,
right heart catheterization was performed. Thus, through
combination of the results from the noninvasive screening
protocol and right heart catheterization, the final PH
diagnosis was established, and patients were categorized
into 5 different groups according to the World Health
Organization (WHO) classification for PH etiology. Treat-
ment was initiated subsequently, and the patients with PH
were followed up regularly during outpatient clinic visits
according to current guidelines.10,13,14 Patients with PAH
were followed up every 3 months, specifically when PAH-
aimed therapy was initiated. Patients with other PH
etiologies were followed up less frequently, however, at
least biannually. For the purpose of the current evaluation,
all-cause mortality was noted during follow-up.
Electrocardiography
The ECGs were first stored digitally; thereafter, they were
exported from the ECG database management system and
analyzed with the MATLAB-based (The MathWorks, Natick,
MA) computer program LEADS (Leiden University Medical
Center, Leiden, The Netherlands). Details on the technical
background of LEADS have been reported previously.15 In
short, the standard 10-second ECG was averaged into 1 single
beat thatwas subsequently converted into a vectorcardiographic
beat in a largely automated process. Besides heart rate, QRS
duration, and QT interval (corrected for heart rate according to
the Fridericia formula), the software quantitated the magnitude
and orientation of themeanQRS and T integral vectors, defined
as azimuth (horizontal vector orientation, in degrees) and
elevation (vertical vector orientation, in degrees).16 Thus, the
angle between QRS and T vectors, the QRS-T angle, wascalculated, andVG vector, including theVGx, was derived (see
Fig. 1).9 In a previous study, healthy subjects had a VGx of 24
mV·ms or higher.9 Therefore, with the purpose to analyze this
cutoff value in a clinical context, the current patient population
was subdivided into a group with a VGx less than 24 mV·ms
and a group with a VGx 24 mV·ms or higher.
Echocardiography
Imaging took place in the left lateral decubitus position on
a commercially available system (Vivid Seven; General
Electric–Vingmed, Milwaukee, WI). Regular images were
obtained, and specific attention was addressed to the
measurement of the RV to right atrial pressure gradient or
tricuspid regurgitant jet gradient (TR gradient) and the
derived estimation of the SPAP.8 The estimated SPAP was
defined as the RV to right atrial pressure gradient added to
the right atrial pressure. Right atrial pressure was estimated 5
to 15 mm Hg, according to the diameter and inspiratory
collapse of the inferior caval vein.17 If adequate measure-
ment of the TR gradient could not be obtained in the apical 4-
chamber position, the measurement was repeated in the
short-axis view at the level of the aorta and, if necessary, in
the subcostal view. If this still did not result in adequate
measurement of the TR gradient, agitated saline was used to
improve the signal intensity of the TR jet.14
Right heart catheterization
Right heart catheterization was performed according to the
international guidelines for invasive hemodynamic assessment
of PAH.18 For the current analysis, the SPAP, the diastolic
Fig. 2. Results of the screening algorithm for patients suspected of PAH. In total, 216 patients were screened noninvasively. After noninvasive screening, 143
patients were suspected of PH, and 73 patients had no PH. In 89 patients, suspected of PAH, right heart catheterization was performed, which confirmed PH in 63
patients. After noninvasive screening and right heart catheterization, PH was diagnosed in 117 patients.
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Measurements were obtained with the patient in supine position
with a Swan-Ganz catheter placed in the pulmonary artery.Statistical analysis
To investigate how elevated pulmonary pressure was
reflected in ECG changes, Pearson correlation coefficients
were determined between ECG characteristics and the
echocardiographically estimated SPAP, which is currently
the gold standard for noninvasive pulmonary pressure
estimation. Furthermore, the odds ratio of a VGx less than
24 mV·ms as compared with 24 mV·ms or higher was
calculated for the presence of an estimated SPAP 40 mm Hg
or higher, which corresponds to the echocardiographic
diagnosis of PH. In addition, the odds ratio of an abnormal
VGx was calculated for the final diagnosis of PH, which was
established after patients completed the noninvasive screen-
ing protocol and, if necessary, right heart catheterization.
Furthermore, a receiver operating characteristic curve
analysis was performed to determine the diagnostic accuracy
of the above-described VGx cutoff (b24 mV·ms) and 3 other
cutoff levels (30, 35, and 40 mV·ms). Thereafter, the 3-year
survival characteristics were investigated in patients with
PH. For this purpose, univariate and multivariate (adjusted
for sex, age, heart rate, and WHO PH classification) Cox
proportional hazard regression analysis was performed, in
which the VGx was entered into the regression equation as a
continuous variable. It was previously noted that PAH
patients with most extensive RV disease typically present
with a VGx less than 0 mV·ms.9 Therefore, all-causemortality Kaplan-Meier curve of patients with a VGx less
than 0 mV·ms was compared with the Kaplan-Meier curve of
patients with a VGx of 0 mV·ms or higher. A log-rank test
was performed to assess whether the survival curves differed
significantly between both groups.
Where appropriate, continuous variables are reported as
mean ± SD, binary logistic and Cox proportional hazard
regression coefficients are reported with 95% confidence
interval (CI). P b .05 was considered statistically significant.Results
General and disease specific characteristics of the
patient population
A total of 216 patients (82 male, 38.8%) were screened
for the presence of PAH. Overall, the average age was
54.6 ± 16.4 years at the time of screening. After initial
noninvasive screening, 143 patients were suspected of PH
(see Fig. 2), mainly because of an elevated SPAP (≥40
mm Hg) as estimated echocardiographically (n = 114). In
29 of the 143 patients, there was no echocardiographic
evidence for PH. Nonetheless, a high suspicion of PAH
was present in these patients, as a consequence of the
severity of symptoms, as a result of abnormal functional
tests, or because of radiologic findings.
From the group of 143 suspected PH patients, 89
underwent right heart catheterization. Right heart catheteri-
zation was not performed in the remaining 54 patients in
whom an elevated SPAP was found echocardiographically.
This group consisted of patients with clinically and
Table 2
Electrocardiographic characteristics
No PH
(n=98)
PH
(n=117)
P R estimated
SPAP
(n = 203)
P
Heart rate
(beats per
minute)
72 ± 13 79 ± 17 b.001 0.17 .016
QRS duration
(ms)
93 ± 22 102 ± 25 .007 0.22 .002
QTc interval
(ms)
403 ± 33 417 ± 40 .004 0.27 b.001
Mean QRS 352 ± 175 397 ± 219 .102 0.24 .001
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patients in whom left-sided heart failure was undisputable
and right heart catheterization would have no further
therapeutic consequences.
After noninvasive screening of all patients and right
heart catheterization in the patients in whom it was
indicated, PH was diagnosed in 117 patients. The
characteristics of these patients are listed in Table 1. In
49 patients (42%), WHO group I (previously referred to as
primary PH) was diagnosed. Left ventricular or valvular
disease and hypoxic lung disease were other frequently
occurring causes of PH (Table 1).vector
magnitude
(μV)
QRS axis
azimuth
(deg)
38 ± 45 37 ± 90 .925 −0.15 .036
QRS axis
elevation
(deg)
15 ± 24 13 ± 36 .608 −0.09 .219
Mean T vector
magnitude
(μV)
164 ± 76 153 ± 112 .399 −0.02 .881
T axis
azimuth
(deg)
−40 ± 32 −11 ± 75 b.001 0.36 b.001
T axis
elevation
(deg)
20 ± 17 16 ± 29 .198 0.04 .569
QRS-T
angle (deg)
83 ± 36 111 ± 43 b.001 0.33 b.001
Ventricular 59 ± 25 41 ± 22 b.001 −0.34 b.001Electrocardiographic diagnosis of elevated
pulmonary pressure
The ECG parameters are summarized in Table 2. Patients
with PH had a higher heart rate and a longer QRS duration
and QTc interval as compared with patients without PH.
Furthermore, the angle between the depolarization and
repolarization vector, or QRS-T angle, was significantly
wider. However, as compared with the other ECG and VCG
parameters, the most prominent difference between PH
patients and patients without PH was observed in the VGx,
which was significantly lower in PH patients. A less
pronounced VGx difference between patients with and
patients without PH was observed in those who had either a
history of left-sided heart disease or a history of a WHO
group V–related disease (eg, sarcoidosis) (see Fig. 3).Table 1
Patient characteristics
No PH
(n = 99)
PH
(n = 117)
P
Clinical characteristics
Age (y) 54.1 ± 15.4 55.9 ± 16.1 .405
Range 22.4-80.0 17.4-94.1
Sex (male/female) 39/60 43/74 .690
Functional class (NYHA) 1.9 ± 0.8 2.6 ± 0.7 b.001
Main risk factor for developing PH (n)
Congenital systemic-pulmonary shunt 5 35
Connective tissue disease 27 7
Autoimmune disease 2 5
Liver cirrhosis 9 4
Pulmonary embolism 23 6
Hypoxic lung disease 13 20
Left ventricular/valvular disease 5 30
Other or no specific risk factor 15 4
Echocardiography
Estimated SPAP (mm Hg) 31 ± 9 61 ± 20 b.001
Right heart catheterization 26 63
SPAP (mm Hg) 27 ± 6 65 ± 21 b.001
DPAP (mm Hg) 11 ± 4 27 ± 13 b.001
MPAP (mm Hg) 17 ± 4 40 ± 13 b.001
WHO PH classification 117
I (%) 49 (42%)
II (%) 31 (26%)
III (%) 14 (12%)
IV (%) 6 (5%)
V (%) 3 (3%)
Combined (%) 14 (12%)
NYHA indicates New York Heart Association; DPAP, diastolic pulmonary
artery pressure. Numbers correspond to n, unless mentioned otherwise.
gradient
magnitude
(mV·ms)
Ventricular
gradient
azimuth
(deg)
−6 ± 33 24 ± 73 b.001 0.20 .004
Ventricular
gradient
elevation
(deg)
26 ± 17 22 ± 30 .315 0.01 .839
VGx (mV·ms) 44 ± 23 14 ± 27 b.001 −0.64 b.001
Azimuth: horizontal vector orientation (degrees); elevation: vertical vector
orientation (degrees).The correlations between the SPAP, as estimated with
echocardiography, and the ECG parameters are summarized
in Table 2. The VG vector demonstrated to be inversely
correlated with the estimated SPAP, as was the VGx, which
demonstrated the strongest correlation with the SPAP (R =
−0.64, P b .001). The negative correlation denoted that an
increasing SPAP was associated with a decreasing VGx.
Hence, a reduced VGx represented an elevated SPAP.
To further explore the clinical applicability of the VGx,
patients with an abnormal VGx (b24 mV·ms) were
compared with patients with a normal VGx. Thereafter, the
odds ratio of having a reduced VGx for the presence of
elevated pulmonary pressure was calculated. Patients with a
reduced VGx (b24 mV·ms, n = 97) exhibited an odds ratio of
11.3 (95% CI, 5.7-22.3; P b .001) for the echocardiographic
diagnosis of PH, as compared with patients with a normal
Fig. 3. Mean VGx according to patient history. Patients were subdivided into
different groups according to the WHO classification for PH etiology. Group
I refers to primary forms of PAH. Patients in group II have a history of left-
sided heart disease. Patients in group III have a history of pulmonary disease.
Group IV refers to a history of pulmonary embolism. Group V is the
miscellaneous category and mostly existed of patients with sarcoidosis.
Mean and SEM were plotted to visualize the differences in VGx between
patients with and patient without PH.
Fig. 4. Survival characteristics in PH patients. The dashed line depicts the
survival characteristics of patients with a VGx of 0 mV·ms or higher. The
solid line indicates patients with a VGx of less than 0 mV·ms, which
previously has been associated with severe RV pressure overload. The
numbers below signify patients at risk per group.
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disease resulted in an odds ratio of 17.4 (95% CI, 7.5-40.5;
P b .001). Furthermore, in patients with a reduced VGx, the
odds ratio for the presence of the final PH diagnosis, which
was established after patients completed the noninvasive
diagnostic algorithm and (if necessary) right heart catheteri-
zation, was 7.9 (95% CI, 4.2-14.7; P b .001). For the final PH
diagnosis, the odds ratio was 9.0 (95% CI, 4.4-18.4; P b
.001), when patients with a history of left-sided heart disease
were excluded.
Receiver operating characteristic curve analysis was done
to study the diagnostic performance of the VGx for the
detection of elevated SPAP as estimated with echocardiog-
raphy and for the final diagnosis of PH, which was
established with noninvasive screening and right heart
catheterization (Table 3). The application of the VGx for
detection of an elevated SPAP as estimated with echocar-
diography revealed an area under the curve of 0.83 (P b
.001). The 24-mV·ms cutoff was associated with a sensitivity
of 70% and a specificity of 83%. A VGx cutoff of 40 mV·ms
yielded a sensitivity of 87% and a specificity of 61%.
Exclusion of patients with a history of left-sided heart
disease increased the area under the curve to 0.88 (P b .001).
Whereas the 24-mV·ms cutoff was associated with a
sensitivity of 73% and a specificity of 85% after exclusion
of patients with left-sided heart disease, the 40-mV·ms cutoff
had a sensitivity of 90% and a specificity of 67% (Table 3).Table 3
Diagnostic accuracy of different VGx cutoffs
WHO group II patients
included
WHO group II patients
excluded
Sens (%) Spec PPV NPV Sens Spec PPV NPV
Estimated SPAP ≥40 mm Hg
b24 mV·ms 71 81 81 70 73 85 85 73
b30 mV·ms 77 79 81 75 79 83 85 77
b35 mV·ms 82 69 76 77 83 73 78 79
b40 mV·ms 87 61 72 80 90 67 76 85
Numbers correspond with percentage. NPV indicates negative predictive
value; PPV, positive predictive value; Sens, sensitivity; Spec, specificity.Mortality risk and VGx
During a 3 year follow-up of the PH patients (n = 117), 23
patients (19.7%) died. The average follow-up time was 21.8 ±
13.1 months. Univariate survival analysis revealed that a
reduced VGx was significantly associated with the increased
incidence of all-cause mortality. The crude hazard ratio was
1.018 (95% CI, 1.003-1.034; P = .020), per mV·ms decrease
in VGx. After multivariate correction for age, sex, heart rate,
and WHO classification group, the hazard ratio was 1.025
(95% CI, 1.006-1.045; P = .012) per mV·ms decrease in VGx.
In patients with a VGx of 0 mV·ms or higher, survival
was 88% at 1 year and 84% at 3 years (Fig. 4). In patients
with a VGx of less than 0 mV·ms, which is associated with
more severe RV pressure overload, survival was 77% at 1
year and 66% at 3 years. This resulted in a 20% 3-year
survival difference between patients with a VGx of less than
0 mV·ms as compared with patients with a VGx of 0 mV·ms
or higher, log-rank P = .02 (Fig. 4).Discussion
Key findings were that (1) the VGx correlated inversely
with pulmonary pressure, (2) an abnormally reduced VGx
showed a prominent association with the presence of PH, and
(3) a severely decreased VGx was related with increased
mortality in patients with PH.
In a recent study on healthy subjects and patients with
idiopathic forms of PH, a reduced VGx was related to
elevated pulmonary pressures and to increased RV mass and
size.9 In the current analysis, in which patients with various
forms of PH were included, a similar association between the
VGx and elevated pulmonary pressures was observed. The
VGx correlated inversely with the peak RV pressure as
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significantly elevated in patients with an abnormally reduced
VGx (b24 mV·ms).
Pulmonary hypertension causes elevated RV wall stress
and leads to RV hypertrophy as a consequence of RV
remodeling. Both increased wall stress as well as hypertro-
phy result in ECG changes. The extent and visibility of those
changes depend not only on the height of the pulmonary
pressure and on the degree of RV remodeling but also on the
ECG parameter that is used. Classic 12-lead surface ECG
criteria rely on depolarization characteristics that relate to
RV hypertrophy. Unfortunately, RV hypertrophy is a
relatively late phenomenon that becomes apparent in
advanced stages of PH. Therefore, regular surface ECG-
derived criteria are not well suited for early detection of
increased pulmonary pressure. Previous studies demonstrated
that VCG criteria, specifically the criteria that also incorpo-
rate repolarization characteristics, can more reliably detect
elevated pulmonary pressure, also in earlier stages of the
disease.19-22 In another study, diagnostic performance of
standard ECG criteria was compared with VCG criteria,
including the VGx, in a homogeneous population of
idiopathic PAH patients.9 This demonstrated that the T-
integral vector was more affected in terms of magnitude and
orientation as compared with the QRS-integral vector.
Nonetheless, the VG vector, which incorporates depolariza-
tion and repolarization, had the best diagnostic accuracy for
the detection of RV overload. The current evaluation
confirmed these findings in a heterogeneous population of
patients who were referred for PAH screening. The best
correlations were observed between the pulmonary pressure
and the VCG parameters that incorporated depolarization and
repolarization characteristics, such as the VG. A VGx of less
than 24 mV·ms, which was the lower limit of a normal VGx
in the study by Henkens et al,9 demonstrated to be associated
with an almost 8-fold increased risk for the presence of
idiopathic PH as compared with patients with a normal VGx.
In the current study, an odds ratio of 7.9 was found for a VGx
of less than 24 mV·ms, which is comparable with results of
the study of Henkens et al.9
The VG, defined as the QRST integral, can be calculated
on the standard ECG as well as the VCG and represents the
heterogeneity in action potential durations within the heart.23
Previous studies have shown that RV overload causes distinct
alterations in QRS and T vector loops. Cowdery et al24
indicated the implications of a hypertrophic RV for the QRS
vector loop, and Kawaguchi21 showed the value of the T
vector loop area. Pulmonary hypertension and resultant RV
overload are associated with a relatively lower contribution of
LV electrical forces. As a consequence, the VG vector
reduces in magnitude and becomes oriented more posteriorly
(see Fig. 1). Both these characteristics are reflected in the
projection of the VGx. Thus, the VGx is a surrogate measure,
optimal for detection of RV overload as demonstrated by the
current and previous evaluations.9,22
The present study is the first in which the association
between a reduced VGx and unfavorable survival charac-
teristics is demonstrated. In both the univariate as well as the
multivariate analysis, a reduced VGx was significantlyassociated with the increased incidence of all-cause
mortality. In patients with PH, irrespective of the cause,
reduced RV function is an important predictor of
mortality.25,26 Patients with a reduced VGx, who have
more elevated RV pressure as compared with patients with a
normal VGx, are likely to have more impaired RV function.
Therefore, a reduced VGx probably identifies the patients
who have decreased RV function and exhibit worse survival
as compared with patients with a higher VGx. The findings
in the current study underscore this concept.
Clinical implications
The ECG-derived VGx could be a good screening tool for
PH in high-risk groups, for example, patients with
pulmonary disease and chronic hypoxemia or patients with
inflammatory connective tissue diseases. Routine ECG
analysis during outpatient clinic visits can be used as an
initial PH screening, specifically in these risk groups.
Referral for echocardiography and further analysis could
be considered as soon as a reduction of VGx occurs.
Nowadays, timely detection is even more important because
early treatment demonstrated to be beneficial in patients
with PAH.6
Currently, several treatment modalities are available for
patients with PAH. Potentially, a therapy-induced reduction
in pulmonary vascular resistance and decrease in RV
overload may be reflected by increased VGx. Therefore,
further studies should assess the association between
treatment effect and changes in VGx magnitude. Besides
the application of the VGx for PH screening and treatment
follow-up, the VGx can also be applied to identify patients
who are at increased risk of all-cause mortality, in whom a
more aggressive treatment regimen may be required. This,
however, has to be confirmed in clinical trials.
Limitations
In the present analysis, the VCG was derived from the
standard ECG using the semiautomated computer program
LEADS, which is a noncommercially available tool for
computerized ECG analysis. Currently, electrocardiographs
do not provide the VGx; thus, it has to be calculated
afterward using dedicated software. Nonetheless, only
limited additions to the ECG analysis software would be
required to provide the VGx fully automatically.Conclusion
A reduced VGx identifies patients with elevated pulmo-
nary artery pressure in a heterogeneous population of
patients suspected of PAH. More importantly, a severely
reduced VGx is associated with increased all-cause mortality
risk in patients with PH.
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